A Novel Influenza A (H1N1) Vaccine in Various Age Groups
Top Cited Papers
Open Access
- 17 December 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (25) , 2414-2423
- https://doi.org/10.1056/nejmoa0908535
Abstract
There is an urgent need for a vaccine that is effective against the 2009 pandemic influenza A (H1N1) virus.Keywords
This publication has 9 references indexed in Scilit:
- Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized TrialClinical Infectious Diseases, 2009
- A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell CultureNew England Journal of Medicine, 2008
- Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007–2008Pediatrics, 2008
- Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old ChildrenThe Journal of Infectious Diseases, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Effectiveness of the 2003–2004 Influenza Vaccine Among Children 6 Months to 8 Years of Age, With 1 vs 2 DosesPediatrics, 2005
- A Comparison of 2 Influenza Vaccine Schedules in 6- to 23-Month-Old ChildrenPediatrics, 2005
- Immunization of elderly people with two doses of influenza vaccineJournal of Clinical Microbiology, 1987